

**Stellenausschreibung für die Stellenbörse der DGEpi/
Job offer for the job portal of the DGEpi**



Position	PhD position on ‘Biomarkers for heart failure: Improving personalised risk prediction in the ageing population’ in Hamburg, Germany
Arbeitgeber/ Employer	Institute of Molecular Biology Mainz
Arbeitsort/ Location	Medical Centre Hamburg-Eppendorf, UKE
Gehalt bzw. Gehaltsstufe/ Salary scale	TVL E13 65%
Arbeitszeit/ Hours	Full time
Vertragsdauer/ Contract type	3 years
Bewerbungsfrist/ Application deadline	31 August 2024
Kontaktperson/ Contact person	coage-recruiting@imb.de
Weitere Bewerbungs- informationen/ Information for applicants	<p>Cardiovascular diseases (CVD) represent the leading non-communicable diseases (NCD) associated with the highest NCD death rates globally. Heart failure (HF), a major CVD, is the most common cause of hospitalization and in-hospital death throughout Germany. The high incidence shows a rising trend as the population ages, and the disease is not only related to high mortality and morbidity, but also to lower quality of life and extensive health expenditures, making it a major public health issue. Due to the growing HF burden, there is a need for improved risk assessment, early detection, and prognostication of HF to facilitate disease management. Existing risk prediction models are usually limited to traditional CVD risk factors. However, those often fail to accurately estimate an individual’s full risk to develop HF, and at granting prognostic utility. Improving these models by adding impactful risk markers is crucial to inform personalised approaches for precision prevention in those at highest risk for developing HF. By exposing the activity of multiple HF-associated pathways and structural changes, circulating and imaging-based biomarkers have the potential to better estimate risk and prognosis in the ageing population, and to out-perform existing risk prediction</p>

	<p>models by adding valuable information and taking into account a comprehensive and differentiated personal profile. The improved personalised risk prediction may lead to a better identification of high-risk individuals, subsequently inform patients in short- and long-term prognosis, therapy and care. Ultimately, this will result in a reduction of HF disease burden and support healthy ageing.</p> <p>Hamburg offers a large-scale dataset from a population-based cohort study including a wide range of deep phenotype variables, also covering lab-based biomarkers, imaging and genetic data, which can be used to address this research topic.</p> <p>Supervision: Stefan Blankenberg (Medical Centre Hamburg-Eppendorf, UKE); The HCHS Study</p>
<p>Datum der Anzeige/ Date posted</p>	<p>01.08.2024</p>
<p>Link zur Stellenausschreibung/ Link to job posting</p>	<p>CHA Mainz</p>